Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
39.29-0.09 (-0.23%)
At close: 03:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close39.38
Open39.18
BidN/A x N/A
AskN/A x N/A
Day's Range39.12 - 39.42
52 Week Range37.88 - 53.86
Volume1,469,142
Avg. Volume1,307,054
Market Cap255.502B
Beta (5Y Monthly)0.21
PE Ratio (TTM)16.37
EPS (TTM)2.40
Earnings DateN/A
Forward Dividend & Yield1.24 (3.10%)
Ex-Dividend DateMar 17, 2022
1y Target Est47.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for RHHBY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ROCHE HOLDINGS AG SPN ADR EACH
    Analyst Report: Roche Holding AGRoche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Benzinga

    Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant

    Roche Holding Ltd (OTC: RHHBF) (OTC: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 Omicron sub-variant is prevalent in the U.S. and quickly spreads to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment stra

  • Reuters

    Roche launches new test to detect fast spreading Omicron sub-variant

    Roche has launched a new PCR test to detect a fast-spreading sub-variant of the Omicron variant of Coronavirus, the Swiss drugmaker said on Thursday. The new test specifically targets the XBB.1.5 Omicron variant and will help researchers closely track the virus’s lineage and provide insights into the epidemiology and impact it has on public health, the company added. The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries, Roche said.

  • GlobeNewswire

    Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant

    This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480 II* and cobas® z480.Results from the test will help closely track the virus’ lineage and provide insights into the epidemiology and impact it has on public health.Concern from the World Health Organisation centres around the XBB.1.5 high transmissibility and growth advantage.1 Basel, 26 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB

Advertisement
Advertisement